Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia

Der Cherng Liang, Lee Yung Shih, Iou Jih Hung, Chao Ping Yang, Shu Huey Chen, Tang Her Jaing, Hsi Che Liu, Wan Hui Chang

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

BACKGROUND. Recently, an internal tandem duplication of the FLT3 gene (FLT3/ITD) was found in approximately 20% of adult acute myeloid leukemia (AML) cases and associated with a poor outcome. However, there are few studies on FLT3/ITD in childhood AML, and the clinical significance of FLT3/ITD is thus unclear. METHODS. FLTS/ITD was analyzed in 80 children with de novo AML. The genomic DNA polymerase chain reaction (PCR) assay was performed to identify FLT3/ITD. Genescan analysis to determine the allelic distribution was then performed for those PCR products with aberrant bands. Direct sequencing of PCR products was also carried out in each sample with FLT3/ITD. RESULTS. The incidence of FLT3/ITD was 11.3% (9 out of 80 patients) in AML, with 25% (3 out of 12 patients) in acute promyelocytic leukemia (APL) and 8.8% (6 out of 68 patients) in non-M3 AML. The size of duplicated fragments varied from 21 base pairs (bp) to 75 bp, and the mutant to wild type ratio of FLT3 ranged from 0.28 to 16.60 in the nine patients with FLT3/ITD. The incidence of FLT3/ITD in childhood AML in patients > 10 years of age was 24%, compared to 5% of those patients ≤ 10 years of age (P = 0.011). The six non-M3 AML patients with FLT3/ITD were all older than 10 years of age. In APL, FLT3/ITD was found in 2 of 2 patients with S-form PML/RARα, compared with 1 in 10 patients with non-S form PML/RARα(P = 0.045). There were no cytogenetic abnormalities or fusion transcripts derived from common specific translocations found in non-M3 AML patients with FLT3/ITD. There was no significant difference in treatment outcome between APL patients with FLT3/ITD and those without FLT3/ITD. The authors failed to find a correlation between the treatment outcome and the presence of FLT3/ITD in non-M3 AML patients. Instead, the authors found that all three patients with a mutant FLT3 to wild type ratio of greater than 2.0 died within eight months after diagnosis; two of them failed to achieve complete remission. CONCLUSIONS. The current study shows that the mutant FLT3 to wild type ratio, but not the presence of FLT3/ITD itself, may serve as a potential marker to improve risk-assessment in childhood AML.

Original languageEnglish
Pages (from-to)3292-3298
Number of pages7
JournalCancer
Volume94
Issue number12
DOIs
Publication statusPublished - Jun 15 2002
Externally publishedYes

Fingerprint

Gene Duplication
Acute Myeloid Leukemia
Acute Promyelocytic Leukemia
Base Pairing
Polymerase Chain Reaction
Incidence
DNA-Directed DNA Polymerase
Chromosome Aberrations

Keywords

  • Childhood acute myeloid leukemia
  • FLT3 internal tandem duplication
  • French-American-British subtype
  • Fusion transcript

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Liang, D. C., Shih, L. Y., Hung, I. J., Yang, C. P., Chen, S. H., Jaing, T. H., ... Chang, W. H. (2002). Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer, 94(12), 3292-3298. https://doi.org/10.1002/cncr.10598

Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. / Liang, Der Cherng; Shih, Lee Yung; Hung, Iou Jih; Yang, Chao Ping; Chen, Shu Huey; Jaing, Tang Her; Liu, Hsi Che; Chang, Wan Hui.

In: Cancer, Vol. 94, No. 12, 15.06.2002, p. 3292-3298.

Research output: Contribution to journalArticle

Liang, DC, Shih, LY, Hung, IJ, Yang, CP, Chen, SH, Jaing, TH, Liu, HC & Chang, WH 2002, 'Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia', Cancer, vol. 94, no. 12, pp. 3292-3298. https://doi.org/10.1002/cncr.10598
Liang, Der Cherng ; Shih, Lee Yung ; Hung, Iou Jih ; Yang, Chao Ping ; Chen, Shu Huey ; Jaing, Tang Her ; Liu, Hsi Che ; Chang, Wan Hui. / Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. In: Cancer. 2002 ; Vol. 94, No. 12. pp. 3292-3298.
@article{38219a0ffa6c49c786c7db7fbec6edd5,
title = "Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia",
abstract = "BACKGROUND. Recently, an internal tandem duplication of the FLT3 gene (FLT3/ITD) was found in approximately 20{\%} of adult acute myeloid leukemia (AML) cases and associated with a poor outcome. However, there are few studies on FLT3/ITD in childhood AML, and the clinical significance of FLT3/ITD is thus unclear. METHODS. FLTS/ITD was analyzed in 80 children with de novo AML. The genomic DNA polymerase chain reaction (PCR) assay was performed to identify FLT3/ITD. Genescan analysis to determine the allelic distribution was then performed for those PCR products with aberrant bands. Direct sequencing of PCR products was also carried out in each sample with FLT3/ITD. RESULTS. The incidence of FLT3/ITD was 11.3{\%} (9 out of 80 patients) in AML, with 25{\%} (3 out of 12 patients) in acute promyelocytic leukemia (APL) and 8.8{\%} (6 out of 68 patients) in non-M3 AML. The size of duplicated fragments varied from 21 base pairs (bp) to 75 bp, and the mutant to wild type ratio of FLT3 ranged from 0.28 to 16.60 in the nine patients with FLT3/ITD. The incidence of FLT3/ITD in childhood AML in patients > 10 years of age was 24{\%}, compared to 5{\%} of those patients ≤ 10 years of age (P = 0.011). The six non-M3 AML patients with FLT3/ITD were all older than 10 years of age. In APL, FLT3/ITD was found in 2 of 2 patients with S-form PML/RARα, compared with 1 in 10 patients with non-S form PML/RARα(P = 0.045). There were no cytogenetic abnormalities or fusion transcripts derived from common specific translocations found in non-M3 AML patients with FLT3/ITD. There was no significant difference in treatment outcome between APL patients with FLT3/ITD and those without FLT3/ITD. The authors failed to find a correlation between the treatment outcome and the presence of FLT3/ITD in non-M3 AML patients. Instead, the authors found that all three patients with a mutant FLT3 to wild type ratio of greater than 2.0 died within eight months after diagnosis; two of them failed to achieve complete remission. CONCLUSIONS. The current study shows that the mutant FLT3 to wild type ratio, but not the presence of FLT3/ITD itself, may serve as a potential marker to improve risk-assessment in childhood AML.",
keywords = "Childhood acute myeloid leukemia, FLT3 internal tandem duplication, French-American-British subtype, Fusion transcript",
author = "Liang, {Der Cherng} and Shih, {Lee Yung} and Hung, {Iou Jih} and Yang, {Chao Ping} and Chen, {Shu Huey} and Jaing, {Tang Her} and Liu, {Hsi Che} and Chang, {Wan Hui}",
year = "2002",
month = "6",
day = "15",
doi = "10.1002/cncr.10598",
language = "English",
volume = "94",
pages = "3292--3298",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia

AU - Liang, Der Cherng

AU - Shih, Lee Yung

AU - Hung, Iou Jih

AU - Yang, Chao Ping

AU - Chen, Shu Huey

AU - Jaing, Tang Her

AU - Liu, Hsi Che

AU - Chang, Wan Hui

PY - 2002/6/15

Y1 - 2002/6/15

N2 - BACKGROUND. Recently, an internal tandem duplication of the FLT3 gene (FLT3/ITD) was found in approximately 20% of adult acute myeloid leukemia (AML) cases and associated with a poor outcome. However, there are few studies on FLT3/ITD in childhood AML, and the clinical significance of FLT3/ITD is thus unclear. METHODS. FLTS/ITD was analyzed in 80 children with de novo AML. The genomic DNA polymerase chain reaction (PCR) assay was performed to identify FLT3/ITD. Genescan analysis to determine the allelic distribution was then performed for those PCR products with aberrant bands. Direct sequencing of PCR products was also carried out in each sample with FLT3/ITD. RESULTS. The incidence of FLT3/ITD was 11.3% (9 out of 80 patients) in AML, with 25% (3 out of 12 patients) in acute promyelocytic leukemia (APL) and 8.8% (6 out of 68 patients) in non-M3 AML. The size of duplicated fragments varied from 21 base pairs (bp) to 75 bp, and the mutant to wild type ratio of FLT3 ranged from 0.28 to 16.60 in the nine patients with FLT3/ITD. The incidence of FLT3/ITD in childhood AML in patients > 10 years of age was 24%, compared to 5% of those patients ≤ 10 years of age (P = 0.011). The six non-M3 AML patients with FLT3/ITD were all older than 10 years of age. In APL, FLT3/ITD was found in 2 of 2 patients with S-form PML/RARα, compared with 1 in 10 patients with non-S form PML/RARα(P = 0.045). There were no cytogenetic abnormalities or fusion transcripts derived from common specific translocations found in non-M3 AML patients with FLT3/ITD. There was no significant difference in treatment outcome between APL patients with FLT3/ITD and those without FLT3/ITD. The authors failed to find a correlation between the treatment outcome and the presence of FLT3/ITD in non-M3 AML patients. Instead, the authors found that all three patients with a mutant FLT3 to wild type ratio of greater than 2.0 died within eight months after diagnosis; two of them failed to achieve complete remission. CONCLUSIONS. The current study shows that the mutant FLT3 to wild type ratio, but not the presence of FLT3/ITD itself, may serve as a potential marker to improve risk-assessment in childhood AML.

AB - BACKGROUND. Recently, an internal tandem duplication of the FLT3 gene (FLT3/ITD) was found in approximately 20% of adult acute myeloid leukemia (AML) cases and associated with a poor outcome. However, there are few studies on FLT3/ITD in childhood AML, and the clinical significance of FLT3/ITD is thus unclear. METHODS. FLTS/ITD was analyzed in 80 children with de novo AML. The genomic DNA polymerase chain reaction (PCR) assay was performed to identify FLT3/ITD. Genescan analysis to determine the allelic distribution was then performed for those PCR products with aberrant bands. Direct sequencing of PCR products was also carried out in each sample with FLT3/ITD. RESULTS. The incidence of FLT3/ITD was 11.3% (9 out of 80 patients) in AML, with 25% (3 out of 12 patients) in acute promyelocytic leukemia (APL) and 8.8% (6 out of 68 patients) in non-M3 AML. The size of duplicated fragments varied from 21 base pairs (bp) to 75 bp, and the mutant to wild type ratio of FLT3 ranged from 0.28 to 16.60 in the nine patients with FLT3/ITD. The incidence of FLT3/ITD in childhood AML in patients > 10 years of age was 24%, compared to 5% of those patients ≤ 10 years of age (P = 0.011). The six non-M3 AML patients with FLT3/ITD were all older than 10 years of age. In APL, FLT3/ITD was found in 2 of 2 patients with S-form PML/RARα, compared with 1 in 10 patients with non-S form PML/RARα(P = 0.045). There were no cytogenetic abnormalities or fusion transcripts derived from common specific translocations found in non-M3 AML patients with FLT3/ITD. There was no significant difference in treatment outcome between APL patients with FLT3/ITD and those without FLT3/ITD. The authors failed to find a correlation between the treatment outcome and the presence of FLT3/ITD in non-M3 AML patients. Instead, the authors found that all three patients with a mutant FLT3 to wild type ratio of greater than 2.0 died within eight months after diagnosis; two of them failed to achieve complete remission. CONCLUSIONS. The current study shows that the mutant FLT3 to wild type ratio, but not the presence of FLT3/ITD itself, may serve as a potential marker to improve risk-assessment in childhood AML.

KW - Childhood acute myeloid leukemia

KW - FLT3 internal tandem duplication

KW - French-American-British subtype

KW - Fusion transcript

UR - http://www.scopus.com/inward/record.url?scp=0037096857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037096857&partnerID=8YFLogxK

U2 - 10.1002/cncr.10598

DO - 10.1002/cncr.10598

M3 - Article

VL - 94

SP - 3292

EP - 3298

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -